



Dkt. 55873-C/JPW/AJM/JCS *IFew*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Anne Marie Schmidt, et al.
U.S. Serial No.: 10/666,513 Examiner: J. Andres
Filed : September 19, 2003 Art Unit: 1646
For : EXTRACELLULAR NOVEL RAGE BINDING PROTEIN (EN-RAGE) AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
June 6, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references. 37 C.F.R. §1.97(c) provides that an Information Disclosure Statement will be considered if it is (a) filed before the mailing date of a final action under §1.311, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, and (b) it is accompanied by the fee set forth in 37 C.F.R. §1.17(p). The fee for filing an Information Disclosure Statement under 37 C.F.R. §1.17(p) is \$180.00, and a check for that amount is enclosed herewith. Accordingly, this Information Disclosure Statement is being timely filed.

This Information Disclosure Statement is submitted as a supplement to the Information Disclosure Statements filed January 6, 2004 and March 22, 2005. The applicants direct the Examiner's attention to

Applicants : Anne Marie Schmidt, et al.
U.S. Serial No: 10/666,513
Filed : September 19, 2003
Page 2

the following references which are listed on the enclosed PTO-1449 form attached hereto as **Exhibit 1**.

1. March 24, 2005 Communication from the European Patent Office transmitting a Supplementary Partial European Search Report Under Rule 45 EPC in connection with European Patent Application No. 99953081.9, filed October 6, 1999 (**Exhibit 2**).
2. Miyata, T., et al., "The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- β_2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis," Journal of Clinical Investigation 98: 1088-1094 (1996) (**Exhibit 3**).
3. Hori, O., et al., "The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products of the development of vascular disease in diabetes mellitus," Nephrology Dialysis Transplantation 11: 13-16 (1996) (**Exhibit 4**).
4. Li, J., et al., "Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products," Journal of Biological Chemistry 272: 16498-16506 (1997) (**Exhibit 5**).
5. Hofmann, M., et al., "EN-RAGE (extracellular novel-RAGE binding protein) activates endothelial cells and macrophages to mediate inflammatory responses,"

Applicants : Anne Marie Schmidt, et al.
U.S. Serial No: 10/666,513
Filed : September 19, 2003
Page 3

Circulation 98: I316 (1998) (**Exhibit 6**).

Applicants request that the Examiner review the references and make them of record in the subject application.

No fee, other than the \$180.00 fee for filing an Information Disclosure Statement under 37 C.F.R. §1.17(p), is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

6/6/05
Date
Alan J. Morrison
Reg. No. 37,399

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400

Form PTO-144

U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Application Number	10/666,513
Filing Date	September 19, 2003
First Named Inventor	Ann Marie Schmidt
Art Unit	1646
Examiner Name	J. Andres
Attorney Docket No.	55873- C/JPW/AJM/JCS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		March 24, 2005 Communication from the European Patent Office transmitting a Supplementary Partial European Search Report Under Rule 45 EPC in connection with European Patent Application No. 99953081.9, filed October 6, 1999	
		Miyata, T., et al., "The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- β_2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis," Journal of Clinical Investigation 98: 1088-1094 (1996)	
		Hori, O., et al., "The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products of the development of vascular disease in diabetes mellitus," Nephrology Dialysis Transplantation 11: 13-16 (1996)	
		Li, J., et al., "Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products," Journal of Biological Chemistry 272: 16498-16506 (1997)	
		Hofmann, M., et al., "EN-RAGE (extracellular novel-RAGE binding protein) activates endothelial cells and macrophages to mediate inflammatory responses," Circulation 98: I316 (1998)	

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.